GALMED PHARMACEUTICALS LTD - SHS NEW (GLMD)

CUSIP: M47238122

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class
Equity / SHS NEW
Total 13F shares
143,537
Share change
+143,537
Total reported value
$419,148
Price per share
$2.99
Number of holders
12
Value change
+$419,148
Number of buys
12

Quarterly Holders Quick Answers

What is CUSIP M47238122?
CUSIP M47238122 identifies GLMD - GALMED PHARMACEUTICALS LTD - SHS NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS NEW (GLMD) as of Q2 2023

As of 30 Jun 2023, GALMED PHARMACEUTICALS LTD - SHS NEW (GLMD) was held by 12 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 143,537 shares. The largest 10 holders included BVF INC/IL, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, MORGAN STANLEY, WELLS FARGO & COMPANY/MN, TSFG, LLC, Federation des caisses Desjardins du Quebec, Tower Research Capital LLC (TRC), BOURGEON CAPITAL MANAGEMENT LLC, and Allworth Financial LP. This page lists 12 institutional shareholders reporting positions in this security for the Q2 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.